|04/25/17||Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar|
|REDWOOD CITY, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), announced today that it completed the initial phases of the Biologics Price Competition and Innovation Act (BPCIA) patent exchange procedure with Amgen for Coherus’ Neulasta (pegfilgrastim) biosimilar candidate, CHS-1701. Of the two patents originally listed by Amgen in the process, the parties have reached agreement on a single patent for potential litigation, U.S. patent 8,273,707 (the ‘707 pat... |
|04/24/17||Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th|
|REDWOOD CITY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2017 financial results will be released after market close on Monday, May 8, 2017. At 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing first quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus... |
|03/27/17||Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development|
|REDWOOD CITY, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the appointment of Erik Wiberg as Executive Vice President of Corporate Development. Mr. Wiberg joins Coherus with more than 30 years of experience, including more than 18 years in various business development and corporate finance roles at biopharmaceutical companies, and 13 years in healthcare investment banking and equity research. In this position, Mr. Wiberg will be responsi... |
|03/13/17||Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results|
|REDWOOD CITY, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate events and reported financial results for the fourth quarter and full year 2016.
Corporate Highlights for the Fourth Quarter 2016 Include:
Oncology therapeutic franchise:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate)
- Announced that the U.S. FDA has accepted the filing of 351(k) Biologics License Application (BLA) for CHS-1701. The first FDA submissi... |